{"id":"zonisamide-high-dose-group","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-20","effect":"Ataxia"},{"rate":"10-20","effect":"Dizziness"},{"rate":"5-15","effect":"Anorexia"},{"rate":"5-10","effect":"Cognitive impairment"},{"rate":"1-4","effect":"Nephrolithiasis (kidney stones)"},{"rate":"1-3","effect":"Hypohidrosis (decreased sweating)"}]},"_chembl":{"chemblId":"CHEMBL750","moleculeType":"Small molecule","molecularWeight":"212.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Zonisamide works through multiple mechanisms: it blocks voltage-gated sodium channels to reduce repetitive neuronal firing, inhibits T-type calcium channels, and enhances the activity of GABA, the brain's primary inhibitory neurotransmitter. These combined effects suppress abnormal electrical activity in the brain, making it effective for seizure control. The high-dose formulation delivers increased drug exposure for enhanced therapeutic effect.","oneSentence":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:46.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy for partial seizures)"},{"name":"Generalized tonic-clonic seizures"}]},"trialDetails":[{"nctId":"NCT00404248","phase":"PHASE1, PHASE2","title":"Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2007-01","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT01127165","phase":"PHASE4","title":"Low and High Dose Zonisamide in Children as Monotherapy","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2006-03","conditions":"Epilepsy","enrollment":125},{"nctId":"NCT00552526","phase":"PHASE4","title":"Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2007-11","conditions":"Epilepsy, Mental Retardation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"zonisamide high dose group","genericName":"zonisamide high dose group","companyName":"Eisai Korea Inc.","companyId":"eisai-korea-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition. Used for Epilepsy (adjunctive therapy for partial seizures), Generalized tonic-clonic seizures.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}